Medical Review Policy

Who medically reviews GLP1 One Rx content

Three named people are responsible for every page of medical content on this site:

• Dr. Parmis — Editorial Lead. Medical researcher (Western University of Health Sciences). Researches and edits every page.
• Dr. Jonathan Snipes, MD — Medical Reviewer. Medically reviews every page. NPI 1821250077; NPPES lists him as an active M.D.
• Kim Callender, NP (FNP-BC) — Lead Reviewer. Medically reviews every page. NPI 1144661760; NPPES lists her as a Family Nurse Practitioner (FNP-BC).

The review workflow

1. Research and draft. Dr. Parmis researches and drafts the page from the source hierarchy below. Every numeric claim cites a Tier 1 or Tier 2 source.
2. Medical review. Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC) check: (a) drug class, (b) dosing schedules, (c) contraindications and adverse events, (d) FDA-approval status, (e) clinical trial citations (PMID and primary endpoint), and (f) the line between compounded and FDA-approved products. Comments go back to the editor.
3. Revision. Dr. Parmis addresses the reviewers' comments and returns the revised page for confirmation.
4. Final edit. Dr. Parmis does a final pass for clarity, structure and internal links.
5. Publication. The page is published with the reviewers' names in the byline and a reviewedBy reference in its structured data.

Source hierarchy

Content is sourced from three tiers, with priority given to Tier 1:

• Tier 1 — Peer-reviewed clinical trials (NEJM, JAMA, Lancet, Annals); FDA databases (Orange Book, Drugs@FDA, 503B Outsourcing Facility Registration); FDA Drug Safety Communications; manufacturer prescribing information (USPI); USP General Chapters (USP <71>, <85>, <797>, <800>).
• Tier 2 — State pharmacy board records; LegitScript verification; Better Business Bureau (BBB); independent review sites; AMA, ASBP, OMA position statements; provider clinical protocols when publicly published.
• Tier 3 — Editorial test orders, structured patient interviews, social-media patient signal aggregation. Tier 3 sources are used only as context and never to support a primary clinical claim.

Review cadence

• Per-publication. Every new page is medically reviewed before publication.
• Monthly. Drug fact verification (FDA status, label expansions, recalls) across all 14 medication pages.
• Quarterly. Full review of the v4.1 methodology.
• Within 7 days. Updates following FDA Drug Safety Communications, new pivotal trial publications, regulatory enforcement actions affecting the GLP-1 / compounded GLP-1 class, or labeling changes.

What is reviewed

Medical review applies to all claims of the following types:

• Drug pharmacology — mechanism, half-life, receptor activity, metabolism, drug-drug interactions.
• Dosing — titration schedules, maintenance doses, dose-reduction triggers.
• Contraindications & warnings — absolute and relative contraindications, boxed warnings, populations at elevated risk (pregnancy, MEN-2, MTC family history, severe gastroparesis, pancreatitis history).
• Adverse events — frequency, severity, monitoring guidance.
• Clinical trial citation — trial name, PMID, primary endpoint, effect size, statistical confidence interval.
• FDA-approval status — brand vs compounded distinction, semaglutide-base vs salt-form distinction, compounded medications are not FDA-approved.
• Pharmacy oversight — 503A vs 503B distinction, USP testing standards, CoA availability.

Disclosures & integrity

• Ownership. GLPONERX LLC is not owned by any drug manufacturer, telehealth provider or compounding pharmacy.
• No paid placement. Providers cannot pay to appear in the directory or rank higher. Rankings follow the published methodology.
• Reviewers and money. Medical reviewers check accuracy only. They do not set rankings or scores.
• Not medical advice. Content is educational. Information published here is not a substitute for individualized advice from a licensed clinician. Patients should never start, modify, or discontinue a prescription medication based on website content alone.

Corrections

If you identify a medical accuracy concern, email glponerx@gmail.com with the page URL, the specific claim, and a Tier 1 or Tier 2 source supporting your concern. Response within 72 hours; warranted corrections published within 7 days, with a dated note in the corrections log.

Reviewer credentials

Dr. Jonathan Snipes, MD — NPI 1821250077. The federal NPPES registry lists him as an active M.D. Check the record.

Kim Callender, NP (FNP-BC) — NPI 1144661760. NPPES lists her as a Family Nurse Practitioner (FNP-BC). Check the record.

Questions about our reviewers: glponerx@gmail.com.